Evidence map›Paper›PMID 33840201›Full record

ReviewHypertension (Dallas, Tex. : 1979)2021

Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Naureen Fatima, Sanket N Patel, Tahir Hussain

Abstract readReview
In one paragraph

Review in Hypertension (Dallas, Tex. : 1979), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Review
  2. Beneficial effects of the ATERJ open research · 2026
    Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Brassinin Induces HMolecules (Basel, Switzerland) · 2025
    Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Megalin: A Sidekick or Nemesis of the Kidney?Journal of the American Society of Nephrology : JASN · 2025
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Naureen FatimaFrom the Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, TX.
Sanket N PatelFrom the Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, TX.
Tahir HussainFrom the Department of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, TX.

Funding

Renal Angiotensin ll Receptor Function in ObesityR01DK061578 · NIDDK · UNIVERSITY OF HOUSTON · PI HUSSAIN, TAHIR · 2003 to 2020
$4.3M
Protective Arm of the Renin Angiotensin System in Obese KidneyR01DK117495 · NIDDK · UNIVERSITY OF HOUSTON · PI HUSSAIN, TAHIR · 2018 to 2021
$1.6M
NIDDK NIH HHS R01 DK061578NIDDK NIH HHS R01 DK117495
6 · The paper itself

Abstract

The renin-angiotensin system is of vital significance not only in the maintenance of blood pressure but also because of its role in the pathophysiology of different organ systems in the body. Of the 2 Ang II (angiotensin II) receptors, the AT

Indexed as

HypertensionRenin-Angiotensin SystemAnimalsBlood PressureCOVID-19COVID-19 Drug TreatmentHumansPharmacological PhenomenaReceptor, Angiotensin, Type 2Receptor, Angiotensin, Type 2alamandineblood pressurehypertensioninflammationobesity

Identifiers

PMID33840201
PMCPMC8115429

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.